Ectdmodule1usa1
Chemical structure of Levetiracetam, showing a pyrrolidone ring attached to an ethyl group and a carbamoyl group at the chiral carbon.*
Levetiracetam Tablet
Product Images NDC 13668-015
17 FDA label images from Torrent Pharmaceuticals Limited · Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 17 technical images submitted to the FDA as part of the official labeling for Levetiracetam (NDC 13668-015). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Torrent Pharmaceuticals Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Ectdmodule1usa10
Label for Levetiracetam Tablets, USP 250 mg, oral tablets. The label indicates a package of 60 tablets, with storage instructions and dispensing warnings. It is manufactured by Torrent Pharmaceuticals Limited and labeled for prescription use only (Rx only). The label includes the NDC 13668-014-60 and a barcode.*
Ectdmodule1usa11
Label for Levetiracetam Tablets USP 500 mg oral tablets by Torrent Pharmaceuticals Limited. The label indicates a package containing 60 tablets and includes storage instructions, usual dosage notice, manufacturing information from India, and the note 'Rx only.' The label also requests pharmacists to dispense with a medication guide provided separately.*
Ectdmodule1usa12
Levetiracetam Tablets USP 750 mg oral tablets label displaying a bottle containing 60 tablets. The label includes dosage strength 750 mg, NDC 13668-016-60, and instructions for storage and dispensing. Manufactured by Torrent Pharmaceuticals Ltd., India, and for Torrent Pharma Inc., Levittown, PA. The label is marked Rx only and includes a pharmacist dispensing note.*
Ectdmodule1usa13
Levetiracetam Tablets, USP 1000 mg oral tablets packaging label shows a bottle containing 60 tablets. Manufactured by Torrent Pharmaceuticals Ltd., the label includes storage instructions, NDC 13668-017-60, pharmacist dispensing instructions, and the labeler Torrent Pharma. The label states Rx only and emphasizes child-resistant packaging.*
Ectdmodule1usa14
Levetiracetam Tablets, USP 250 mg oral tablet packaging label for 60 tablets by Torrent Pharmaceuticals Limited. The label shows storage instructions, dispensing requirements, manufacturer information, NDC 13668-014-60, and a barcode. It states the product is prescription only (Rx) and includes a prominent red banner with the dosage strength 250 mg.*
Ectdmodule1usa15
Levetiracetam Tablets, USP 500 mg oral tablets bottle label showing a package size of 60 tablets. The label includes storage instructions, dispensing guidance, and manufacturing details by Torrent Pharmaceuticals Ltd., India, and manufactured for Torrent Pharma Inc., Levittown, PA. The label features a barcode and states Rx only.*
Ectdmodule1usa16
Levetiracetam Tablets, USP 750 mg label for a bottle containing 60 tablets. The label includes storage instructions, dosage caution, manufacturer details (Torrent Pharmaceuticals Ltd., India, and Torrent Pharma Inc., USA), a barcode, and a note for pharmacists to dispense with medication guide. Marked Rx only.*
Ectdmodule1usa17
Levetiracetam Tablets USP 1000 mg oral tablets label, showing package size of 60 tablets. Manufactured by Torrent Pharmaceuticals Ltd., India, and marketed for Torrent Pharma Inc., Levittown, PA. The label includes storage instructions, usual dosage note, National Drug Code (NDC) 13668-017-60, and states 'Rx only.'*
Ectdmodule1usa2
A bar chart showing the percentage of patients across three groups: Placebo, Levetiracetam 1000 mg/day, and Levetiracetam 3000 mg/day. The y-axis represents the percentage of patients, with bars indicating approximately 7.4% for placebo, 37.1% for 1000 mg/day, and 39.6% for 3000 mg/day Levetiracetam doses.*
Ectdmodule1usa3
A bar chart showing the percentage of patients for three groups: Placebo, Levetiracetam 1000 mg/day, and Levetiracetam 2000 mg/day. The chart displays an increasing trend in patient percentage from placebo at 6.3% to Levetiracetam 2000 mg/day at 35.2%, with Levetiracetam 1000 mg/day at 20.8%.*
Ectdmodule1usa4
A vertical bar chart comparing the percentage of patients between two groups: Placebo (N=104) with 14.4%, and Levetiracetam 3000 mg/day (N=180) with 39.4%. The y-axis represents the percentage of patients, ranging from 0% to 45%.*
Ectdmodule1usa5
A bar chart comparing the percentage of patients responding in two groups: Placebo (N=97) at 19.6% and Levetiracetam (N=101) at 44.6%. The vertical axis represents the percentage of patients, ranging from 0% to 45%.*
Ectdmodule1usa6
A bar graph compares the percentage of patients in two groups: Placebo with 51 participants and Levetiracetam with 58 participants. The placebo group shows approximately 19.6% of patients, while the Levetiracetam group shows about 43.1%, indicating a higher patient percentage in the Levetiracetam group.*
Ectdmodule1usa7
A bar graph comparing the percentage of patients between two groups: Placebo (N=84) with 45.2% and Levetiracetam (N=79) with 72.2%. The vertical axis is labeled '% of Patients' ranging from 0% to 100%. An asterisk is present above the Levetiracetam bar.*
Ectdmodule1usa8
Ectdmodule1usa9
* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.
